Copper gluconate/disulfiram - Cantex Pharmaceuticals

Drug Profile

Copper gluconate/disulfiram - Cantex Pharmaceuticals

Alternative Names: CX 02; Disulfiram/copper gluconate - Cantex Pharmaceuticals; DSF-Cu

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cantex Pharmaceuticals
  • Class Antineoplastics; Heavy metals; Small molecules
  • Mechanism of Action Aldehyde dehydrogenase inhibitors; Cell death stimulants; Proteasome inhibitors; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Brain metastases; Breast cancer

Most Recent Events

  • 01 May 2017 Cantex Pharmaceuticals intends to initiate phase II trials in Breast cancer in 2018
  • 04 Apr 2017 Cantex Pharmaceuticals intends to initiate phase II trials in Prostate cancer in the second half of 2017
  • 04 Apr 2017 Pharmacodynamics data from a preclinical trial in Glioblastoma and Breast cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top